Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.36 |
| ▸ | TUBB | P07437 | 2/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.36 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16720648 | 0.86 | IDO1 (0.46) | IDO1CDK1CCNB1GSK3BTUBB4A | |
| SCHEMBL16719384 | 0.82 | TGFBR1 (0.36) | IDO1STIM1ORAI1ALDH1A1MAPT | |
| SCHEMBL28895988 | 0.76 | TGFBR1 (0.45) | STIM1ORAI1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL16719832 | 0.74 | SMN1; SMN2 (0.44) | KDM4CALDH1A1L3MBTL1KDM4EHPGD | |
| SCHEMBL10873515 | 0.69 | ERN1 (0.58) | IDO1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2746986 | 0.68 | CA12 (0.43) | MEN1ALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL16719820 | 0.67 | ABL1 (0.43) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL28322749 | 0.66 | ERN1 (0.52) | KMOMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL10892159 | 0.65 | PTPN1 (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1331700 | 0.63 | KDM4C (0.52) | KMOKDM4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | WISTAR INST (US) | 2022-12-15 | — | — | US | claimed |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-02-08 | — | — | US | claimed |
| EP-3068758-B1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2021-09-08 | — | — | EP | claimed |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2020-06-11 | — | — | US | claimed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | claimed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | claimed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | claimed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | claimed |
| US-12258314-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | WISTAR INST (US) | 2022-12-15 | — | — | US | disclosed |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3068758-B1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-9856214-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | IDO1 1284/4885KMO 1416/4885KDM4C 323/4885 |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | IDO1 1284/4885KMO 1416/4885KDM4C 323/4885 |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | MCM5, EBNA1BP2, MLLT1 | IDO1 1406/4885KMO 1149/4885KDM4C 383/4885 |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | IDO1 1284/4885KMO 1416/4885KDM4C 323/4885 |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | IDO1 1284/4885KMO 1416/4885KDM4C 323/4885 |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | IDO1 1284/4885KMO 1416/4885KDM4C 323/4885 |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | EBNA1BP2, MLLT1, PML | IDO1 1284/4885KMO 1416/4885KDM4C 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.